Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Short-term Investments (2016 - 2019)

Akebia Therapeutics has reported Short-term Investments over the past 5 years, most recently at $245000.0 for Q4 2019.

  • Quarterly Short-term Investments fell 99.58% to $245000.0 in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $245000.0 through Dec 2019, down 99.58% year-over-year, with the annual reading at $245000.0 for FY2019, 99.58% down from the prior year.
  • Short-term Investments was $245000.0 for Q4 2019 at Akebia Therapeutics, down from $22.7 million in the prior quarter.
  • Over five years, Short-term Investments peaked at $240.1 million in Q3 2017 and troughed at $245000.0 in Q4 2019.
  • The 5-year median for Short-term Investments is $105.3 million (2019), against an average of $127.6 million.
  • Year-over-year, Short-term Investments skyrocketed 151.44% in 2017 and then plummeted 99.58% in 2019.
  • A 5-year view of Short-term Investments shows it stood at $88.7 million in 2015, then dropped by 17.67% to $73.0 million in 2016, then fell by 19.58% to $58.7 million in 2017, then decreased by 0.49% to $58.4 million in 2018, then plummeted by 99.58% to $245000.0 in 2019.
  • Per Business Quant, the three most recent readings for AKBA's Short-term Investments are $245000.0 (Q4 2019), $22.7 million (Q3 2019), and $49.6 million (Q2 2019).